Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Osaka, OsakaFounded 18971,747 employeesWebsite
A leading Japanese pharmaceutical company under Sumitomo Chemical, focusing on psychiatry & neurology, oncology, and regenerative medicine on a global scale.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| North American Operations | 75% | ¥337.9B | ¥75.7B | 22.4% |
| Japan Market | 20% | ¥92.4B | ¥12.4B | 13.4% |
| Asia | 5% | ¥23.0B | ¥9.5B | 41.1% |
Close (Oct 30, 2026)
¥1,884.5+13.9% (1Y)
Sumitomo Pharma +13.9% over 1Y, 1.4pt above the industry average (23 companies, +12.5%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥453.3B | ¥107.3B | ¥106.9B | ¥804.6B | +13.7% |
| 2025FY | ¥398.8B | ¥28.8B | ¥23.6B | ¥742.6B | +26.8% |
| 2024FY | ¥314.6B | — | — | ¥907.5B | -43.4% |
| 2023FY | ¥555.5B | — | — | ¥1.1T | -0.8% |
| 2022FY | ¥560.0B | ¥60.2B | ¥56.4B | ¥1.3T | +8.5% |
| 2021FY | ¥516.0B | ¥71.2B | ¥56.2B | ¥1.3T | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
